• Sub-chronic Effect Of Co-administration Of Methformine And Amilodipine On Some Haematological Indices In Experimental Animal
    [A CASE STUDY OF WISTAR RATS]

  • CHAPTER FOUR -- [Total Page(s) 6]

    Page 1 of 6

    1 2 3 4 5    Next
    • CHAPTER FOUR
      4.0 Results
      4.1 Hematological parameter in control and test groups
          As summarized in table 1, the mean RBC counts were 7.62 ± 2.83 x1012/L for the control and 6.53 ± 0.57 x1012/L for co-administration of metformin and amlodipine fed groups respectively. Although, decrease in RBC counts was observed in the treated (co-administration of metformin and amlodipine) dose group, these were statistically significant compared to control groups (student t test P<0.05) (table 1). The mean total WBC count in control group was 11.76 ± 0.33 x106/L. It was not significantly (student t test P>0.05) higher in the treated (co-administration of metformin and amlodipine) dose group (12.28 ± 0.72 x106/L) compared with control (table 2).
          The mean PCV was significantly higher in the control group (44.16 ± 2.83 %) than in
      treated group (38.47.60 ± 3.53%) (table 1). The mean control Hb concentration was 14.46 ± 0.72 g/dl. The Hb concentration of the treated group was significantly (P<0.05) lower compared with controls. Also, shown in table 4, are the mean values of MCV for the control and treated group
      which were 57.87 ± 1.67 and 59.52 ± 1.48fl respectively. These values were significantly different from each other among the groups (student t test P<0.05). The mean values of MCH were significantly different among the groups (P<0.05). But the MCHC was not significantly different as compared with controls.
      4.2 Differential white blood cell counts in control and tests groups
          The mean values of neutrophils groups (24.67 ± 4.49% respectively) were significantly (P<0.05) high compared with controls (14.17 ± 3.29 %) (Table 3). The mean value of lymphocytes in the treated group (73.03 ± 0.97 %) was significantly (P<0.05) higher compared with values obtained for control (80.14 ± 4.04 %) groups (table 3). Eosinophils were not significantly different among the groups. Monocyte counts were not significantly different among the groups. Basophil counts were not significantly different among the groups.
      Table 1: Relationship between some red cell indices after co-administration of Metformine and Amlodipine treated Rats and control


      Key
      PCV: packed cell volume
      RBC: red blood cell
      HB: haemoglobin concentration

  • CHAPTER FOUR -- [Total Page(s) 6]

    Page 1 of 6

    1 2 3 4 5    Next
    • ABSRACT - [ Total Page(s): 1 ]ABSTRACTMetformin, which belongs to the biguanide class, is one of the most generally used oral hypoglycemic agents. It has been used for more than 50 years and was approved by the US Food and Drug Administration (FDA) in 1994 (American Diabetes Association, 2009) whereas Amlodipine is a long acting dihydropyridine calcium channel blocker, which is used in the treatment of angina to lower the BP (Blood pressure). the aim is to know the effect of co-administration of this two drugs in Wistar rats ... Continue reading---

         

      APPENDIX A - [ Total Page(s): 1 ]APPENDIXAPPENDIX 1:     MATERIAL USED1% Ammonium oxalate10% Formalin salineAbsorbent paperAutomatic pipetteBrilliant cresyl blueCounting chamber Cyanmethaemoglobin standardDrabkin’s ReagentEDTA sample containerHematoxylin and Eosin stainKhan tubes/rackLeisfhmann stainLight microscopeMicrohaematocrit centrifugeNormal salinePasteur pipettePipette tipsRotary microtomeSpectrophotometerTimer Turk’s solution Universal sample bottle ... Continue reading---

         

      APPENDIX B - [ Total Page(s): 1 ]APPENDIX IITable 1: haematological parameters in control, Metformine treated and Amilodipine treated Rats (Values are expressed as mean ± Standard error of means)                     Group A(1): control (untreated), Group B(2): co-administration of Metformin 0.00264/ml/132g and Amlodipine 0.000849/ml/132g at a single dose for 30 daysPARAMETERS     GROUP A     GROUP   BPacked cell volume (%)    44.16±2.83    38.47±3.53Red blood cell count (x1012/L)    7 ... Continue reading---

         

      LIST OF TABLES - [ Total Page(s): 1 ]LIST OF TABLESTable 1: Haematological parameters in control, Co-administration of Metformin and Amlodipine treated  ... Continue reading---

         

      LIST OF FIGURES - [ Total Page(s): 1 ]LIST OF FIGURESFigure 1: Shows mechanism of action of metformin Figure 2: Shows Pie chat representation of Packed cell volume of control, Co-administration of metformin and amlodipine treated Wistar Rats        Figure 3: Shows Histogram representation of Hemoglobin and red blood cell count of control, Co-administration of metformin and amlodipine treated Wistar Rats   Figure 4: Shows Histogram representation of red cell indicies of control, Co-administration of metformin and amlodipine t ... Continue reading---

         

      TABLE OF CONTENTS - [ Total Page(s): 1 ]TABLE OF CONTENTTitle page   Declaration  Certification  Dedication     Acknowledgement      Table of content      List of table  List of figures     Abstract    CHAPTER ONE1.0 Introduction    1.1 Background of study   1.2 Statement of Problems           1.3 Justifications    1.4 Aims      1.5 Research Objectives       1.6 Research Hypothesis     1.7 Significance of research   CHAPTER TWO2.0 Literature review    2.1 Metformin    2.1.1 ... Continue reading---

         

      CHAPTER ONE - [ Total Page(s): 2 ]CHAPTER ONE1.0    INTRODUCTION1.1 Background of the studyMetformin, which belongs to the biguanide class, is one of the most generally used oral hypoglycemic agents. It has been used for more than 50 years and was approved by the US Food and Drug Administration (FDA) in 1994 (American Diabetes Association, 2009). Currently, many clinical practice guidelines for patients with type 2 diabetes, including the American Diabetes Association (ADA), the European Association for the Study of Diabetes ... Continue reading---

         

      CHAPTER TWO - [ Total Page(s): 12 ]The current use of serum Vitamin B12 level relies on several different range points for Vitamin B12 status. Serum Vitamin B12 level under 148 pmol/L are said to be deficient, low/borderline levels are interpreted from levels between 148-220 pmol/L (Mazokopakis and Starakis, 2012). Normal ranges of Vitamin B12 serum range from 220- 800 pmol/L, levels that exceed this are rarely suspicious in cause, although excessive B12 serum may be a marker of myloproliferative disorders (Pernicova and Korbonit ... Continue reading---

         

      CHAPTER THREE - [ Total Page(s): 4 ]From the above table,Km of rats= 6    Km of human= 37For Amlodipine, Human dose= 10mg/70kg                                        1kg=10/70                     =0.14mg/kgAED of Amilodipine= 0.14×(6/37)                                  =0.02mg/kgAverage weight of experimental Animal is 132g(0.132kg)If 0.02mg of Amlodipine is administered per kg.bw,(0.02×0.132)mg of Amlodipine was administered to ... Continue reading---

         

      CHAPTER FIVE - [ Total Page(s): 2 ]CHAPTER FIVE5.0 DiscussionMetformin (1,1-dimethylbiguanide) is the most widely used drug to treat type 2 diabetes, and is one of only two oral anti-diabetic drugs on the World Health Organization (WHO) list of essential medicines (American Diabetes Association, 2009). Amlodipine is a long acting dihydropyridine calcium channel blocker, which is used in the treatment of angina to lower the BP. Co-administration of Metformin and Amlodipine have been discovered to lead to vitamin B12 deficiency. Al ... Continue reading---

         

      REFRENCES - [ Total Page(s): 4 ]Senol, M.G., Sonmez, G., Ozdag, F. and Saracoglu, M. (2008). Reversible myelopathy with vitamin B12 deficiency. Singapore Medical Journal. 49(11): 330-332.Srinivasan, S., Ambler, G.R., Baur, L.A., Garnett, S.P. and Tepsa, M. (2006). Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. Journal of Clinical Endocrinology and Metabolism. 91: 2074-2080. Sterne, J. (1957). Du nouveau dans les anti ... Continue reading---